sterile water (PF) solution [7484]Type: QS BaseOrder Dose: 844.5 mLPackage: 1,000 mL Flex Cont (0990-7990-09)Calc Dose: 844.5 mLDispense Amount: 844.5 mLCharge Method: Injection Standard (System picked)
Actual Components:
Component
Volume
Concentration
Na contributed
NaCl 23.4%
64 mL
4 mEq/mL
256 mEq
Sodium Acetate
91.5 mL
2 mEq/mL
183 mEq
Sterile Water
844.5 mL
diluent
0
Total
1000 mL
439 mEq
Total Sodium:
Parameter
Value
Total Na⁺
256 + 183 = 439 mEq
Total volume
1000 mL
Na concentration
439 mEq/L
Anion Breakdown:
Anion
Source
Amount
Chloride (Cl⁻)
NaCl 23.4%
256 mEq
Acetate (CH₃COO⁻)
Sodium Acetate
183 mEq
Ratio Cl:Acetate
~58:42
Percentage NaCl:
Step
Calculation
Total Na = 439 mEq/L
Convert to g NaCl equivalent
439 × 58.44 ÷ 1000
= 25.66 g/L
Convert to %
25.66 ÷ 10
NaCl equivalent %
~2.57%
Comparisons:
Solution
Na (mEq/L)
NaCl-equivalent %
0.9% NaCl
154
0.9%
3% NaCl
513
3%
This compounded solution
439
~2.57%
Theoretical 50:50
1257
~7.35%
Pure sodium acetate
2000
~11.7%
Clinical Comparison:
Feature
Standard 3% NaCl
This Compounded Solution
Na (mEq/L)
513
439
Chloride
513 mEq/L
256 mEq/L
Acetate
0
183 mEq/L
Hyperchloremia risk
Higher
Lower
Alkalinizing effect
None
Mild
Sodium delivery
Higher
~15% less than 3% NaCl
This compounded solution delivers 439 mEq/L of sodium — roughly equivalent to a ~2.57% NaCl solution, which is slightly less sodium than standard 3% NaCl (513 mEq/L). However, it offers the advantage of lower chloride load with acetate replacing nearly half the anion burden, reducing risk of hyperchloremic metabolic acidosis.
EMPHASIS (Efficacy and safety of minocycline in patients with acute ischaemic stroke)
Journal
The Lancet
Published in (year)
2026
Authors
Yao Lu, Ling Guan, Jialing Wu, Qianqian Yang, Meiyang Zhang, Dongyang Zhou, Hongqin Yang, Yuesong Pan, Luyan Wang, Baoshan Qiu, Chenhui Liu, Yicong Wang, Yingying Yang, Xuejiao Zhou, Hui Qu, Xiaoling Liao, Liping Liu, Xingquan Zhao, Philip M Bath, S Claiborne Johnston, Pierre Amarenco, Guillaume Turc, Fu-Dong Shi, Yongjun Wang, and Yilong Wang
Institution
Department of Neurology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China (Primary site)
Clinical question
Does oral minocycline treatment initiated within 72 hours of symptom onset improve functional outcomes at 90 days in patients with acute ischaemic stroke compared to placebo?
N (number of subjects)
1,724 patients
Inclusion criteria
Patients aged 18–80 years; ischaemic stroke confirmed by CT or MRI within 72 h of onset; NIHSS score 4–25; level of consciousness score (NIHSS 1a) ≤1; first-ever stroke or pre-stroke mRS score ≤1
Exclusion criteria
Allergy or resistance to tetracycline antibiotics; severe hepatic or renal insufficiency; pregnancy or breastfeeding
Methods
Participants were randomly assigned (1:1) to receive oral minocycline or matching placebo. Minocycline regimen: 200 mg loading dose, followed by 100 mg every 12 h for 4 days (4.5-day total course). Routine treatment followed national guidelines and permitted thrombolysis or thrombectomy
Intervention group n
862 patients
Control group n
862 patients
Primary outcome
Excellent functional outcome at 90 days (mRS 0–1): 52.6% (447/850) in the minocycline group vs. 47.4% (403/851) in the placebo group; adjusted risk ratio (RR) 1.11 (95% CI 1.03–1.20); p=0.0061
Secondary outcome/s
• Ordinal shift (mRS) at 90 days: Favored minocycline; adjusted common odds ratio (cOR) 1.19 (95% CI 1.03–1.38); p=0.018• Change in NIHSS score at 6 days: -2 in minocycline vs. -1 in placebo (adjusted β –0.28, 95% CI –0.50 to –0.05); p=0.015• mRS 0–2 at 90 days: 72.4% vs. 67.8%; RR 1.07 (95% CI 1.02–1.12); p=0.0056• New stroke at 90 days: 5.9% vs. 5.5%; HR 1.09 (95% CI 0.73–1.62); p=0.68
Adverse events or safety outcome
• Serious adverse events: 4.6% (minocycline) vs. 5.9% (placebo); p=0.24• Symptomatic intracranial haemorrhage (sICH) at 6 days: 0.3% vs. 0%• All-cause death at 90 days: 1.6% vs. 2.3%; adjusted HR 0.69 (95% CI 0.35–1.36); p=0.28
Conclusion
Minocycline therapy initiated within 72 h of acute ischaemic stroke provides a significant functional outcome benefit at 90 days compared with placebo, without safety concerns
Critique or limitations
Study conducted exclusively in China (limited generalizability to non-Asian populations); upper age limit of 80; lower than expected treatment effect reduced statistical power for some secondary outcomes; borderline statistical significance sensitive to missing data imputation; non-centralized hs-CRP analysis
Take home message
A short, 4.5-day course of inexpensive oral minocycline started within 72 hours of an acute ischaemic stroke (NIHSS 4-25) is a safe and effective treatment to reduce long-term disability
a rare and frequently fatal complication characterized by rapid-onset cerebral edema following the reconstruction of the cranial vault.
Case Presentation
42/M s/p DHC for refractory ICP after multifocal hemorrhage
Five months post-DC, with severe sinking skin flap (SSF) syndrome, significant 15-mm MLS.
one hour s/p cranioplasty, GTC seizure + rapid neurological decline
CT = diffuse supratentorial and cerebellar edema, new small cortical hemorrhage
Despite aggressive medical Mx and surgical removal of implant –> profound anoxic brain injury.
Pathophysiology of MBSC
“malignant presentation pattern” triggered by sudden restoration of the cranial vault
Pseudointracranial HTN:
Brain chronically adapted to low-pressure state (intracranial hypotension) from open skull and atmospheric pressure cannot handle sudden surge in ICP once skull is sealed
In severe SSF syndrome, intracranial system has low compliance –> restoration of vault –> rapid shift in blood and CSF volumes –> brain unable to buffer –> catastrophic edema
Risk Factors and Clinical Lessons
Severe SSF syndrome and MLS are critical preoperative risk states not just cosmetic concerns
intracranial hypotension and SSF present in essentially all reported cases of MBSC
Lower precranioplasty ICP values also associated with higher likelihood of ICP surge s/p bone flap placement
Immediate postoperative seizures may act as trigger / marker for cascade of intracranial derangement
Proposed Management Pathway
outcomes poor once the MBSC cascade begins
emphasize heightened perioperative vigilance
propose a rescue protocol (Fig. 5):
Identify HR patients with severe SSF and MLS
Frequent neurochecks, avoiding triggers [hypercapnia or hypotension]
If seizure, pupil change, rapid decline –> STAT head CT and hyperosmolar therapy –> emergent re-decompression if diffuse malignant edema confirmed
Families of HR patients should be explicitly counseled that rapid malignant swelling, severe disability, or death can occur even after a technically “routine” cranioplasty.
Source: Walker, A., Feldman, M., & Alvarado-Dyer, R. (2026). Massive brain swelling after cranioplasty in the setting of severe sunken flap syndrome: illustrative case. Journal of Neurosurgery: Case Lessons, 11(15): CASE2659. doi: 10.3171/CASE2659.
According to the proposed management algorithm, the clinical path depends on the location of the hygroma and the presence of symptoms:
1. Ipsilateral Hygromas
Asymptomatic with no mass effect: These are the most common and likely to resolve spontaneously; the recommended approach is observation until the patient is ready for cranioplasty.
Asymptomatic but >10 mm with mass effect OR Symptomatic: For these cases, clinicians should perform serial aspirations or temporary CSF diversion as a “bridge” until cranioplasty can be performed.
2. Contralateral Hygromas
These carry a higher risk for neurological complications because they can cause midline shift.
Asymptomatic with no mass effect: Managed with observation.
Asymptomatic but >10 mm with mass effect OR Symptomatic: These require the insertion of a subdural drain as a bridge to cranioplasty.
3. Bridge to Definitive Treatment
Cranioplasty: This is the definitive treatment. Restoring the dicrotic ICP waveform through cranioplasty results in a resolution rate of nearly 90% for subdural hygromas.
Permanent CSF Diversion: This should be considered in two specific scenarios:
If the patient is not ready for cranioplasty but requires ongoing management.
If the hygroma recurs after the cranioplasty has been completed.
If the patient develops radiographic or clinical hydrocephalus following the cranioplasty.
Clinical Note: If fluid is drained via aspiration or a subdural drain, it should be sent for culture, as meningitis can contribute to CSF malabsorption. Other temporary strategies mentioned in the sources include compression bandages, lumbar or ventricular drains, and Ommaya reservoirs.
Proposed management algorithm for management of hygromas after cranioplasty
Simplified Decision Table:
When ready → proceed with cranioplasty (definitive tx; ~90% resolution rate).
If Sxic or with ME, temporary diversion (IPSI) or subdural drain (CONTRA) prior to OR.
If hygroma recurs or hydrocephalus develops post-cranioplasty → permanent CSF diversion.
Not ready for cranioplasty:
Reminders:
Cranioplasty is the definitive treatment (~90% resolution rate).
All aspirated/drained fluid should be sent for culture (r/o meningitis → CSF malabsorption).
HYDROCEPHALUS
The management algorithm for hydrocephalus (often presenting as ventriculomegaly) following a decompressive hemicraniectomy (DHC) is primarily determined by whether the patient is symptomatic and whether the condition is progressive.
According to the proposed algorithm in the sources, the clinical pathway is as follows:
Initial Assessment
Once a patient develops ventriculomegaly after DHC, they are categorized into two groups:
Symptomatic Patients: These patients should proceed toward permanent CSF diversion, typically a ventriculoperitoneal shunt (VPS). Alternatively, a lumbar puncture (LP) may be performed for further diagnostic evaluation.
Asymptomatic Patients: These patients require serial imaging and clinical examinations to monitor the stability of the ventriculomegaly.
Observation and Progression
For those in the asymptomatic group, the next steps depend on the follow-up findings:
If Ventriculomegaly Remains Stable: The patient should proceed directly to cranioplasty.
If Ventriculomegaly Progresses or Symptoms Develop: The patient is moved into the symptomatic pathway, requiring either a VPS or an LP for further evaluation.
Post-Cranioplasty Monitoring
Following the cranioplasty, the patient must continue to be monitored. If they subsequently develop new symptoms or if imaging shows worsening ventriculomegaly post-operatively, the clinician should again consider proceeding with a VPS or LP evaluation.
Key Clinical Considerations
Distinguishing Hydrocephalus: It is critical to differentiate true symptomatic hydrocephalus from hydrocephalus ex vacuo (non-progressive ventriculomegaly resulting from brain tissue loss), as the latter does not require long-term shunting.
Shunt Specifications: If a VPS is necessary, the sources recommend using an adjustable valve with an anti-siphon device (ideally with a “virtual off” setting) to avoid complications like “sunken brain” or post-trephination syndrome.
Role of Cranioplasty: Cranioplasty is considered the primary management strategy for many CSF-related issues after DHC because it restores normal intracranial dynamics and may resolve non-progressive ventriculomegaly without the need for a permanent shunt.
Management algorithm for intraventricular hydrocephalus after DHC
REFERENCE:
Zima, L., & Kitagawa, R. (2026). Cerebrospinal Fluid Management in the Setting of Decompressive Hemicraniectomy. Neurosurgery Clinics of North America, 37, 233–240. https://doi.org/10.1016/j.nec.2025.12.008
Does a single dose of antibiotics reduce infections in critically ill patients?
Background and Objective
ABI (TBI/stroke) high risk for VAP- 20% to >70% driven by aspiration before intubation and weakened immune system after brain injury.
Aim: Determine if an early, single dose of ceftriaxone can safely decrease early VAP incidence?
Study Methodology
345 comatose adult patients (GCS ≤12) nine ICUs in France requiring ventilation x >=48 hours.
Randomized: Ceftri 2G IV x1 dose within 12h vs placebo
Outcome: proportion early VAP (day 2-7 of vent) confirmed by a masked adjudication committee
RESULTS:
early VAP significantly lower in ceftriaxone group (14% vs 32%)
more ventilator-free days (9 vs. 5) and shorter ICU and hospital LOS
lower 28d mortality rate in ceftriaxone group (15% vs 25%
no adverse effects attributed to the antibiotic – no increase in antibiotic-resistant bacteria (such as ESBL-producing strains) or Clostridium difficile infections within this study’s timeframe
single dose decreased total antibiotic exposure – fewer patients developed infections requiring prolonged curative treatment
Conclusion and Recommendations
single, early dose ceftriaxone is highly effective, safe, and simple intervention for ABI patients
Include in standard prevention bundles for all brain-injured patients requiring mechanical ventilation to improve survival and reduce healthcare costs
Source: Dahyot-Fizelier, C., et al. (2024). “Ceftriaxone to prevent early ventilator-associated pneumonia in patients with acute brain injury: a multicentre, randomised, double-blind, placebo-controlled, assessor-masked superiority trial.” The Lancet Respiratory Medicine, 12(5), 375–385
What is the optimal method for assessing extubation readiness in ABI?
SBTs is standard
primary objective -= evaluate association between SBT modality (T-piece, PSV or CPAP) and the risk of extubation failure within five days
Study Population and Methodology
839/1,512 patients in ENIO
median age 55
most common cause of admission TBI (47.2%)
PSV (51.3%), T-piece (39.2%), and CPAP (9.5%).
median duration for PSV and T-piece trials = 60 minutes, CPAP trials = 120 minutes
Key Findings
neither SBT modality nor duration significantly associated with extubation failure
consistent across various ABI subgroups
Extubation failure (reintubation within five days) in 21.1%
associated with higher mortality, longer ICU stays, increased pulmonary complications
vigorous cough remained the only significant and consistent predictor of extubation success
RSBI and gag reflex not independently predictive of success
higher PEEP at extubation linked to failure in unweighted models, not in weighted models (?marker of illness severity)
Clinical Implications and Conclusions
neurological status and ability to protect the airway (cough strength) more critical than the specific parameters of the SBT
extubation failure in NCC often from impaired airway protection rather than respiratory muscle fatigue, traditional weaning indices lose predictive power
Use neuro-focused, integrated extubation protocols – prioritize neurological recovery and airway patency over specific type or length of a breathing trial
REFERENCE:
Cinotti, R., Mijangos, J. C., Pelosi, P., Haenggi, M., Gurjar, M., Schultz, M. J., Kaye, C., Godoy, D. A., Alvarez, P., Ioakeimidou, A., Ueno, Y., Badenes, R., Suei Elbuzidi, A. A., Piagnerelli, M., Elhadi, M., Reza, S. T., Azab, M. A., McCredie, V., Stevens, R. D., Digitale, J. C., … ENIO Study Group, the PROtective VENTilation network, the European Society of Intensive Care Medicine, the Colegio Mexicano de Medicina Critica, the Atlanréa group and the Société Française d’Anesthésie-Réanimation–SFAR research network (2022). Extubation in neurocritical care patients: the ENIO international prospective study. Intensive care medicine, 48(11), 1539–1550.
Guaifenesin — Increases volume of secretions, reduces viscosity by stimulating vagal gastropulmonary reflex → thins mucus → facilitates productive cough and indirectly reduces cough stimulus
Dextromethorphan (DM) — NMDA receptor antagonist + sigma-1 receptor agonist in the medullary cough center → raises cough threshold centrally; no opioid receptor activity (non-narcotic)
Benzonatate (Tessalon) — Structurally related to tetracaine; anesthetizes peripheral stretch receptors in the lungs, airways, and pleura → dampens afferent limb of cough reflex arc
Codeine — Mu-opioid receptor agonist in the medullary cough center → directly suppresses cough reflex centrally; also reduces secretions via mild anticholinergic effect
Hydrocodone — Potent mu-opioid receptor agonist in the brainstem cough center → strongest central suppression of cough reflex; also depresses respiratory drive at higher doses
Capnography is a vital monitoring tool that measures the amount of carbon dioxide (CO2) exhaled by a patient, providing immediate data on their respiratory and circulatory status. A normal EtCO2 range is between 35 and 45 mmHg.
Physiology and Terminology
Requirements for EtCO2: For a monitor to detect CO2, three systems must be functioning: metabolism (cells producing CO2), perfusion (blood transporting CO2 to the lungs), and ventilation (the physical act of exhaling).
Capnometry vs. Capnography:Capnometry refers to the specific numerical value of CO2, while the capnogram (or capnograph) is the actual waveform displayed on the monitor.
No Lag Time: Unlike pulse oximetry, which can lag behind a patient’s actual status by a minute or more, capnography is instantaneous; if breathing stops, the waveform stops immediately.
The Capnography Waveform
The standard waveform tracks the phases of a single breath:
Phase A–B (Inhalation): The baseline is at zero because no CO2 is moving past the sensor.
Phase B–C (Start of Exhalation): CO2 begins to rise as it is cleared from the airways.
Phase C–D (Expiratory Plateau): This represents the bulk of exhalation.
Point D (End-Tidal Value): This is the peak value at the very end of the breath, representing the actual EtCO2 number.
Phase D–A: The waveform drops back to zero as the patient begins their next inhalation.
Clinical Applications
Endotracheal Tube Confirmation: Waveform capnography is the “gold standard” for confirming and monitoring the correct placement of an endotracheal tube.
Shock and Perfusion: Low EtCO2 readings often indicate shock rather than a breathing problem. If a patient has poor perfusion, CO2 is produced by the cells but cannot be transported to the lungs for exhalation, leading to low monitor readings even if the blood is saturated with CO2.
Cardiac Arrest and CPR:
If EtCO2 is less than 10 mmHg during CPR, chest compressions are likely inadequate.
A sudden spike in EtCO2 (sometimes reaching as high as 90 mmHg) is a highly reliable indicator of the return of spontaneous circulation (ROSC), allowing clinicians to identify a pulse without stopping compressions.
Monitoring Methods
CO2 is detected using infrared sensors through two primary types of devices:
Mainstream: Sampling occurs directly at the airway device (e.g., the end of an ET tube).
Sidestream: A small sample of air is pulled through a thin tube back to the monitor for analysis.
